資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/34426
|
| 標題: | Right ventricular expression of NT-proBNP adds predictive value to REVEAL score in patients with pulmonary arterial hypertension |
| 作者: | Chang, Wei-Ting
Shih, Jhih-Yuan
Hong, Chon-Seng
Lin, Yu-Wen
Chen, Yi-Chen
Ho, Chung-Han
Chen, Zhih-Cherng
Roan, Jun-Neng
Hsu, Chih-Hsin |
| 貢獻者: | Chi Mei Med Ctr, Div Cardiol, Dept Internal Med
Southern Taiwan Univ Sci & Technol, Dept Biotechnol
Natl Cheng Kung Univ, Inst Clin Med, Coll Med
Chi Mei Med Ctr, Dept Med Res
Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm
Natl Cheng Kung Univ Hosp, Div Cardiovasc Surg, Dept Surg
Natl Cheng Kung Univ, Coll Med
Natl Cheng Kung Univ, Med Device Innovat Ctr
Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Internal Med, Coll Med
Natl Cheng Kung Univ Hosp, Dou Liou Branch, Dept Internal Med
Kaohsiung Med Univ, Coll Med, Dept Resp Therapy |
| 關鍵字: | NT-proBNP
RV expression
HF hospitalization
Group I PAH |
| 日期: | 2021 |
| 上傳時間: | 2023-11-11 11:52:05 (UTC+8) |
| 出版者: | WILEY PERIODICALS, INC |
| 摘要: | Aims The Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) risk scores differentiate survivals in patients with pulmonary arterial hypertension (PAH). However, measurements of N-terminal pro B-type natriuretic peptide (NT-proBNP) in the peripheral blood may not adequately reflect early-stage decompensated heart failure (HF). Given that right heart catheterization (RHC) can facilitate measurements of intracardiac NT-proBNP, in this study our aim was to evaluate the predictive role of right ventricular (RV) NT-proBNP measurements in patients with PAH. Methods and results We prospectively collected intracardiac blood samples for NT-proBNP measurements from patients diagnosed with World Health Organization Group I PAH during RHC. Clinical information including the aetiology of PAH (idiopathic, connective tissue disease, or congenital heart disease) and REVEAL scores were recorded. The primary endpoint was hospitalization for decompensated HF; median duration of follow-up was 28 months. Among the 62 patients evaluated, 12 reached the designated endpoint. REVEAL risk scores were higher among patients hospitalized for HF. We detected no significant differences in plasma NT-proBNP levels in peripheral circulation, in the right atrium, or in pulmonary arterial blood; however, significantly higher levels of NT-proBNP were detected in the RV in patients diagnosed with PAH. RV NT-proBNP was a sensitive predictor (cut-off value 1500 pg/mL) of subsequent hospitalization for HF. Our findings indicate that RV NT-proBNP levels add predictive value to REVEAL scores with respect to future hospitalization due to HF. Conclusions Right ventricular NT-proBNP levels combined with REVEAL 2.0 could predict the development of subsequent HF in patients with PAH and may be a potential biomarker. |
| 關聯: | ESC HEART FAIL, v.8, n.4, pp.3082-3092 |
| 顯示於類別: | [醫務管理系(所)] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| ehf2.13410.pdf | | 4820Kb | Adobe PDF | 44 | 檢視/開啟 | | index.html | | 0Kb | HTML | 88 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
